Finance

Beta
Lists
ACRS:NASDAQ
Aclaris Therapeutics Inc
$4.63
+6.68%
(+0.29) 1D
$4.54
-1.94% (-0.090)
After hours
Closed: Jun 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRS...
Open
$4.41
High
$4.67
Low
$4.35
Mkt. cap
646.64M
Avg. vol.
1.31M
Volume
1.51M
52-wk high
$5.15
52-wk low
$1.34
EPS
-$0.56
Beta
0.76
Shares outstanding
139.66M
No. of employees
71
Open
$4.41
High
$4.67
Low
$4.35
Mkt. cap
646.64M
Avg. vol.
1.31M
Volume
1.51M
52-wk high
$5.15
52-wk low
$1.34
EPS
-$0.56
Beta
0.76
Shares outstanding
139.66M
No. of employees
71
News stories
From sources across the web
About Aclaris Therapeutics Inc
CEO-
Employees71
Founded2012
Headquarters-
SectorPharmaceutical industry
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.15 / -$0.16
+3.67%beat
Revenue / Est. (USD)
2.00M / 1.32M
+51.02%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.78M
3.30M
1.30M
2.00M
Cost of goods sold
13.30M
15.48M
18.05M
17.44M
Cost of revenue
13.30M
15.48M
18.05M
17.44M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.39M
4.87M
5.58M
6.74M
Operating expense
5.39M
4.87M
5.58M
6.74M
Total operating expenses
18.68M
20.35M
23.63M
24.19M
Operating income
-16.91M
-17.05M
-22.33M
-22.19M
Other non operating income
961.00K
716.00K
1.30M
854.00K
EBT including unusual items
-15.43M
-14.61M
-19.80M
-19.82M
EBT excluding unusual items
-13.93M
-14.51M
-19.40M
-19.82M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.43M
-14.61M
-19.80M
-19.82M
Net profit margin
-868.26%
-442.98%
-1,528.57%
-993.19%
Earnings per share
-0.13
-0.12
-0.16
-0.15
Interest and investment income
2.02M
1.82M
1.63M
1.51M
Interest expense
-
-
-
-
Net interest expenses
2.02M
1.82M
1.63M
1.51M
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.88M
-17.04M
-22.32M
-22.19M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more